Human Schistosoma haematobium antifecundity immunity is dependent on transmission intensity and associated with immunoglobulin G1 to worm-derived antigens

Journal of Infectious Diseases

Volumn 210, Issue 12, 2014, Pages 2009-2016

  Wilson, Shona ^a   Jones, Frances M ^a   Van Dam, Govert J ^b   Corstjens, Paul L A M ^c   Riveau, Gilles ^d   Fitzsimmons, Colin M ^a   Sacko, Moussa ^e   Vennervald, Birgitte J ^f   Dunne, David W ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Department of Parasitology ^*  (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d INSERM U1019   (France)

^e Institut National de Recherche en Sante Publique Mali   (Mali)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Fecundity; Human; Immunity; Schistosoma haematobium; Transmission

Indexed keywords

GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; PARASITE ANTIGEN; TEGUMENT ALLERGEN LIKE 1; UNCLASSIFIED DRUG; HELMINTH ANTIBODY; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGE; ANTIBODY RESPONSE; ANTIFECUNDITY IMMUNITY; ARTICLE; CHILD; CONTROLLED STUDY; HUMAN; IMMUNITY; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; PARASITE LOAD; PARASITE PHENOMENA AND FUNCTIONS; PARASITE TRANSMISSION; PRIORITY JOURNAL; SCHISTOSOMA HEMATOBIUM; WORM FECUNDITY; ANIMAL; BLOOD; COHORT ANALYSIS; FEMALE; FERTILITY; IMMUNOLOGY; MALE; MALI; PARASITOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; SCHISTOSOMIASIS HAEMATOBIA; THEORETICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FERTILITY; HUMANS; IMMUNOGLOBULIN G; MALE; MALI; MODELS, THEORETICAL; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMIASIS HAEMATOBIA; YOUNG ADULT;

EID: 84925546428     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu374     Document Type: Article

References (39)

1. WHO. Schistosomiasis: population requiring preventive chemotherapy and number of people treated in 2010. Wkly Epidemiol Rec 2012;87:37-44.
2. van der Werf MJ, de Vlas SJ, Brooker S, et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 2003;86:125-39.
3. WHO. Current estimated total number of individuals with morbidity and mortality due to Schistosomiasis haematobium and S.mansoni infection in sub-Saharan Africa. http://www.who.int/schistosomiasis/epidemiology/table/en/index.html. Accessed 8 July 2014.
4. Smith JH, Kamel IA, Elwi A, Von Lichtenberg F. A quantitative post mortem analysis of urinary schistosomiasis in Egypt. I. Pathology and pathogenesis. Am J Trop Med Hyg 1974;23:1054-71.
5. Vennervald BJ, Polman K. Helminths and malignancy. Parasite Immunol 2009;31:686-96.
6. Kjetland EF, Ndhlovu PD, Gomo E, et al. Association between genital schistosomiasis and HIV in rural Zimbabwean women. AIDS 2006;20:593-600.
7. Hagan P, Blumenthal UJ, Dunn D, Simpson AJ, Wilkins HA. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature 1991;349:243-5.
8. Wilkins HA, Goll PH, Marshall TF, Moore PJ. Dynamics of Schistosoma haematobium infection in a Gambian community. III. Acquisition and loss of infection. Trans Royal Soc Trop Med Hyg 1984;78:227-32.
9. Fitzsimmons CM, Jones FM, Stearn A, et al. The Schistosoma mansoni tegumental-allergen-like (TAL) protein family: influence of developmental expression on human IgE responses. PLoS Neg Trop Dis 2012;6:e1593.
10. Fitzsimmons CM, Jones FM, Pinot de Moira A, et al. Progressive crossreactivity in IgE responses: an explanation for the slow development of human immunity to schistosomiasis?. Infect Immun 2012;80:4264-70.
11. Woolhouse ME, Taylor P, Matanhire D, Chandiwana SK. Acquired immunity and epidemiology of Schistosoma haematobium. Nature 1991;351:757-9.
12. King CH, Keating CE, Muruka JF, et al. Urinary tract morbidity in schistosomiasis haematobia: associations with age and intensity of infection in an endemic area of Coast Province, Kenya. Am J Trop Med Hyg 1988;39:361-8.
13. Hatz CF, Vennervald BJ, Nkulila T, et al. Evolution of Schistosoma haematobium-related pathology over 24 months after treatment with praziquantel among school children in southeastern Tanzania. Am J Trop Med Hyg 1998;59:775-81.
14. Wagatsuma Y, Aryeetey ME, Sack DA, Morrow RH, Hatz C, Kojima S. Resolution and resurgence of Schistosoma haematobium-induced pathology after community-based chemotherapy in Ghana, as detected by ultrasound. J Infect Dis 1999;179:1515-22.
15. Mitchell KM, Mutapi F, Savill NJ, Woolhouse ME. Protective immunity to Schistosoma haematobium infection is primarily an anti-fecundity response stimulated by the death of adult worms. Proc Natl Acad Sci U S A 2012;109:13347-52.
16. Bushara HO, Majid AA, Saad AM, et al. Observations on cattle schistosomiasis in the Sudan, a study in comparative medicine. II. Experimental demonstration of naturally acquired resistance to Schistosoma bovis. Am J Trop Med Hyg 1980;29:442-51.
17. Bushara HO, Hussein MF, Majid MA, Musa BE, Taylor MG. Observations on cattle schistosomiasis in the Sudan, a study in comparative medicine. IV. Preliminary observations on the mechanism of naturally acquired resistance. Am J Trop Med Hyg 1983;32:1065-70.
18. Boulanger D, Warter A, Sellin B, et al. Vaccine potential of a recombinant glutathione S-transferase cloned from Schistosoma haematobium in primates experimentally infected with an homologous challenge. Vaccine 1999;17:319-26.
19. Bushara HO, Bashir ME, Malik KH, et al. Suppression of Schistosoma bovis egg production in cattle by vaccination with either glutathione S-transferase or keyhole limpet haemocyanin. Parasit Immunol 1993;15:383-90.
20. Bergwerff AA, van Dam GJ, Rotmans JP, Deelder AM, Kamerling JP, Vliegenthart JF. The immunologically reactive part of immunopurified circulating anodic antigen from Schistosoma mansoni is a threoninelinked polysaccharide consisting of → 6) - (beta-D-GlcpA-(1 → 3)) - beta-D-GalpNAc-(1 → repeating units. J Biol Chem 1994;269:31510-7.
21. de Water R, Fransen JA, Deelder AM. Ultrastructural localization of the circulating anodic antigen in the digestive tract of Schistosoma mansoni using monoclonal antibodies in an immunogold labeling procedure. Am J Trop Med Hyg 1986;35:549-58.
22. Polman K, Engels D, Fathers L, Deelder AM, Gryseels B. Day-to-day fluctuation of schistosome circulating antigen levels in serum and urine of humans infected with Schistosoma mansoni in Burundi. Am J Trop Med Hyg 1998;59:150-4.
23. Agnew A, Fulford AJ, Mwanje MT, et al. Age-dependent reduction of schistosome fecundity in Schistosoma haematobium but not Schistosoma mansoni infections in humans. Am J Trop Med Hyg 1996;55:338-43.
24. Wilson S, Jones FM, Fofana HK, et al. Rapidly boosted Plasma IL-5 induced by treatment of human schistosomiasis haematobium is dependent on antigen dose, IgE and eosinophils. PLoS Neg Trop Dis 2013;7:e2149.
25. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 1972;14:397-400.
26. Fitzsimmons CM, Stewart TJ, Hoffmann KF, Grogan JL, Yazdanbakhsh M, Dunne DW. Human IgE response to the Schistosoma haematobium 22.6 kDa antigen. Parasite Immunol 2004;26:371-6.
27. Riveau G, Deplanque D, Remoue F, et al. Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Neg Trop Dis 2012;6:e1704.
28. Black CL, Mwinzi PN, Muok EM, et al. Influence of exposure history on the immunology and development of resistance to human schistosomiasis mansoni. PLoS Neg Trop Dis 2011;4:e637.
29. Corstjens PL, van Lieshout L, Zuiderwijk M, et al. Up-converting phosphor technology-based lateral flow assay for detection of Schistosoma circulating anodic antigen in serum. J Clin Microbiol 2008;46:171-6.
30. Corstjens PL, de Dood CJ, Kornelis D, et al. Tools for diagnosis, monitoring and screening of Schistosoma infections utilizing lateral-flow based assays and upconverting phosphor labels. Parasitology 2014. In press.
31. Agnew A, Fulford AJ, De Jonge N, et al. The relationship between worm burden and levels of a circulating antigen (CAA) of five species of Schistosoma in mice. Parasitology 1995;111(Pt 1):67-76.
32. Polman K, De Vlas SJ, Van Lieshout L, Deelder AM, Gryseels B. Evaluation of density-dependent fecundity in human Schistosoma mansoni infections by relating egg counts to circulating antigens through Deming regression. Parasitology 2001;122:161-7.
33. Webster BL, Southgate VR, Littlewood DT. A revision of the interrelationships of Schistosoma including the recently described Schistosoma guineensis. Int J Parasit 2006;36:947-55.
34. Lawton SP, Hirai H, Ironside JE, Johnston DA, Rollinson D. Genomes and geography: genomic insights into the evolution and phylogeography of the genus Schistosoma. Parasit Vectors 2011;4:131.
35. Remoue F, To Van D, Schacht AM, et al. Gender-dependent specific immune response during chronic human schistosomiasis haematobia. Clin Exp Immunol 2001;124:62-8.
36. Grzych JM, De Bont J, Liu J, et al. Relationship of impairment of schistosome 28-kilodalton glutathione S-transferase (GST) activity to expression of immunity to Schistosoma mattheei in calves vaccinated with recombinant Schistosoma bovis 28-kilodalton GST. Infect Immun 1998;66:1142-8.
37. Naus CW, van Dam GJ, Kremsner PG, Krijger FW, Deelder AM. Human IgE, IgG subclass, and IgM responses to worm and egg antigens in schistosomiasis haematobium: a 12-month study of reinfection in Cameroonian children. Clin Inf Dis 1998;26:1142-7.
38. Tran MH, Pearson MS, Bethony JM, et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med 2006;12:835-40.
39. Ahmad G, Zhang W, Torben W, et al. Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. J Infect Dis 2011;204:1437-49.